Skip to main content
Fig. 7 | Particle and Fibre Toxicology

Fig. 7

From: The antihyperlipidemic effects of fullerenol nanoparticles via adjusting the gut microbiota in vivo

Fig. 7

Fullerenol NPs interact with gut microbiota during in vitro gut flora fermentation. a Fullerenols concentration changes in the fermentation solution; b effects of the final concentrations of different fullerenols after in vitro fermentation; c-e responses of Bifidobacterium, Clostridium IV, and Allbaculum spp. to inulin and fullerenol NPs; *P < 0.05, **P < 0.01, ***P < 0.001 vs NC. f PET images of 64Cu- C60 at 0.5, 1, 2, and 6 h after single oral administration. g Excretion curves of 64Cu-C60 at 1, 2, 4, 6, and 24 h after single oral administration. All data points represent three animals per group. The total excretion was the sum of percentages of 64Cu in all the waste (∑0-turine + ∑0-t feces) during 0-t not at the time point

Back to article page